Johnson & Johnson’s 1Q net rockets 6.9% on drug, device sales

Big jumps in sales of prescription drugs and medical devices helped Johnson & Johnson boost its firstquarter profit nearly 7%, blowing past Wall Street forecasts.

The health care giant on Tuesday raised and narrowed its financial forecasts for 2021, and its shares jumped more than 2.3% in New York trading.

The one weak spot was a small drop in consumer health sales, which saw a surge in 2020’s first quarter, when nervous consumers stocked up on over-thecounter medicines and hygiene products as the coronavirus pandemic set in and lockdowns began.

Meanwhile, Johnson & Johnson last week paused administration of its covid-19 vaccine over worries that roughly one in a million vaccine recipients developed unusual blood clots along with low levels of blood platelets. One of them died.

On Tuesday, the European Medicines Agency said its safety committee’s analysis found that risks of those clots and low platelets is very small but should be listed as a rare side effect of the vaccine. The committee declared the vaccine’s benefits outweigh risks of side effects.

Johnson & Johnson, the world’s biggest maker of health care products, last week delayed the start of its European vaccine rollout over the issue. After the medicines agency’s an

nouncement, the company said it will resume shipments to EU member states, plus Norway and Iceland. It’s up to those countries whether to allow administration of the vaccine, but the agency said it was “confident” the Johnson & Johnson shot could be rolled out appropriately.

The maker of Tylenol and Acuvue contact lenses still awaits U.S. health officials’ ruling on the clotting issue, which could come Friday. The one-dose shot is seen as crucial for vaccinating people in remote areas and in poor countries with limited medical infrastructure.

Johnson & Johnson reported first-quarter net income of $6.2 billion, or $2.32 per share, up 6.9% from $5.8 billion, or $2.17 per share, a year earlier. Adjusted earnings amounted to $6.92 billion, or $2.59 per share, 28 cents more than analysts expected.

The company, based in New Brunswick, N.J., reported revenue of $22.32 billion, above the $21.82 billion analysts had anticipated.

Johnson & Johnson said it now expects full-year earnings in the range of $9.42 to $9.57 per share, compared with $9.40 to $9.60 in its January forecast. It anticipates revenue in the range of $90.6 billion to $91.6 billion, versus its January forecast of $90.5 billion to $91.7 billion.

“Our first-quarter 2020 results give us even more confidence in our future,” after a year of uncertainty and lockdowns amid the pandemic, Chief Financial Officer Joe Wolk told analysts on a conference call to discuss the quarterly results.

Wolk noted the company plans this year to apply for 10 regulatory approvals of new medicines and additional uses for existing drugs.

In March, the company’s covid-19 vaccine received emergency use authorization from regulators in the U.S., the European Union and elsewhere. After the clotting problem developed, Johnson & Johnson last week paused all vaccinations, including in ongoing tests of the vaccine.

In addition, quality lapses at one of the key manufacturers helping to make the vaccine forced Johnson & Johnson to discard roughly 15 million doses that didn’t meet quality standards and then to halt production at that factory, while the U.S. Food and Drug Administration investigates.

Johnson & Johnson officials said it’s too soon to determine whether that will affect its commitments to provide 100 million doses in the U.S. by June and a total of 1 billion doses globally this year.

During the quarter, sales of prescription drugs climbed 9.6%, to $12.2 billion, in the quarter, led by Stelara for psoriasis and other inflammatory disorders, schizophrenia medicine Invega Sustenna, and cancer drugs Darzalex and Imbruvica. Johnson & Johnson reported $100 million in initial sales of its covid-19 vaccine.

Sales of medical devices and diagnostic products jumped 10.9%, to $6.58 billion. Consumer health sales dipped 2.3%, to $3.54 billion.

Edward Jones analyst Ashtyn Evans called the results solid, noting Johnson & Johnson’s prescription drugs business “continues to grow above the market, and the medical-device growth is strong as it recovers from the pandemic,” which has caused delays in elective surgeries.

CFRA analyst Sel Hardy raised his recommendation on Johnson & Johnson shares to “Buy” from “Hold” and boosted his 12-month stock target price $17 to $177.

Johnson & Johnson shares rose $3.79 Tuesday to close at $166.48.